{"id":544375,"date":"2015-11-30T18:00:30","date_gmt":"2015-11-30T17:00:30","guid":{"rendered":"https:\/\/hpsitaly.healthcare\/?p=544375"},"modified":"2022-04-11T18:27:02","modified_gmt":"2022-04-11T16:27:02","slug":"valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia","status":"publish","type":"post","link":"https:\/\/hpsitaly.healthcare\/en\/aboutpharmacoeconomics-eng\/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia\/","title":{"rendered":"Valutazione di costo-efficacia di ponatinib nella terapia della Leucemia Mieloide Cronica in Italia"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\" style=\"--awb-text-transform:none;\"><p><strong>AboutPharmacoEconomics Anno II, N. 4, dicembre 2015<\/strong><\/p>\n<p><strong>Tratto da: Lucioni C, Iannazzo S, Mazzi S, et al. Global &amp; Regional Health<\/strong><br \/>\n<strong>Technology Assessment 2015; 2 (1): 1-16<\/strong><\/p>\n<p><strong>Indice<\/strong><\/p>\n<ul>\n<li>Premessa<\/li>\n<li>La terapia clinica della LMC<\/li>\n<li>L\u2019esito terapeutico<\/li>\n<li>Lo studio di HTA<\/li>\n<li>Bibliografia<\/li>\n<\/ul>\n<\/div><div style=\"text-align:left;\"><a class=\"fusion-button button-flat button-xlarge button-default fusion-button-default button-1 fusion-button-default-span fusion-button-default-type popmake-543312 \" target=\"_self\" href=\"#\"><span class=\"fusion-button-text awb-button__text awb-button__text--default\">Download PDF<\/span><\/a><\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":64199,"featured_media":545229,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[1002],"tags":[],"class_list":["post-544375","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aboutpharmacoeconomics-eng"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Valutazione di costo-efficacia di ponatinib nella terapia della Leucemia Mieloide Cronica in Italia - HPS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/hpsitaly.healthcare\/en\/aboutpharmacoeconomics-eng\/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valutazione di costo-efficacia di ponatinib nella terapia della Leucemia Mieloide Cronica in Italia - HPS\" \/>\n<meta property=\"og:url\" content=\"https:\/\/hpsitaly.healthcare\/en\/aboutpharmacoeconomics-eng\/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia\/\" \/>\n<meta property=\"og:site_name\" content=\"HPS\" \/>\n<meta property=\"article:published_time\" content=\"2015-11-30T17:00:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-11T16:27:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2015\/11\/VALUTAZIONE-DI-COSTO-EFFICACIA-DI-PONATINIB-NELLA-TERAPIA-DELLA-LEUCEMIA-MIELOIDE-CRONICA-IN-ITALIA.png\" \/>\n\t<meta property=\"og:image:width\" content=\"574\" \/>\n\t<meta property=\"og:image:height\" content=\"827\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Eleonora Zaghis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Eleonora Zaghis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/hpsitaly.healthcare\/en\/aboutpharmacoeconomics-eng\/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia\/\",\"url\":\"https:\/\/hpsitaly.healthcare\/en\/aboutpharmacoeconomics-eng\/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia\/\",\"name\":\"Valutazione di costo-efficacia di ponatinib nella terapia della Leucemia Mieloide Cronica in Italia - HPS\",\"isPartOf\":{\"@id\":\"https:\/\/hpsitaly.healthcare\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/hpsitaly.healthcare\/en\/aboutpharmacoeconomics-eng\/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/hpsitaly.healthcare\/en\/aboutpharmacoeconomics-eng\/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2015\/11\/VALUTAZIONE-DI-COSTO-EFFICACIA-DI-PONATINIB-NELLA-TERAPIA-DELLA-LEUCEMIA-MIELOIDE-CRONICA-IN-ITALIA.png\",\"datePublished\":\"2015-11-30T17:00:30+00:00\",\"dateModified\":\"2022-04-11T16:27:02+00:00\",\"author\":{\"@id\":\"https:\/\/hpsitaly.healthcare\/#\/schema\/person\/ac9678267e7fdb22ca687b10475393bd\"},\"breadcrumb\":{\"@id\":\"https:\/\/hpsitaly.healthcare\/en\/aboutpharmacoeconomics-eng\/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/hpsitaly.healthcare\/en\/aboutpharmacoeconomics-eng\/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/hpsitaly.healthcare\/en\/aboutpharmacoeconomics-eng\/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia\/#primaryimage\",\"url\":\"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2015\/11\/VALUTAZIONE-DI-COSTO-EFFICACIA-DI-PONATINIB-NELLA-TERAPIA-DELLA-LEUCEMIA-MIELOIDE-CRONICA-IN-ITALIA.png\",\"contentUrl\":\"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2015\/11\/VALUTAZIONE-DI-COSTO-EFFICACIA-DI-PONATINIB-NELLA-TERAPIA-DELLA-LEUCEMIA-MIELOIDE-CRONICA-IN-ITALIA.png\",\"width\":574,\"height\":827,\"caption\":\"VALUTAZIONE DI COSTO-EFFICACIA DI PONATINIB NELLA TERAPIA DELLA LEUCEMIA MIELOIDE CRONICA IN ITALIA\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/hpsitaly.healthcare\/en\/aboutpharmacoeconomics-eng\/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/hpsitaly.healthcare\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Valutazione di costo-efficacia di ponatinib nella terapia della Leucemia Mieloide Cronica in Italia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/hpsitaly.healthcare\/#website\",\"url\":\"https:\/\/hpsitaly.healthcare\/\",\"name\":\"HPS\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/hpsitaly.healthcare\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/hpsitaly.healthcare\/#\/schema\/person\/ac9678267e7fdb22ca687b10475393bd\",\"name\":\"Eleonora Zaghis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/hpsitaly.healthcare\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11db2ac5895a8a4b942ea1e775b297fb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11db2ac5895a8a4b942ea1e775b297fb?s=96&d=mm&r=g\",\"caption\":\"Eleonora Zaghis\"},\"url\":\"https:\/\/hpsitaly.healthcare\/en\/author\/eleonora-zaghis\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Valutazione di costo-efficacia di ponatinib nella terapia della Leucemia Mieloide Cronica in Italia - HPS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/hpsitaly.healthcare\/en\/aboutpharmacoeconomics-eng\/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia\/","og_locale":"en_US","og_type":"article","og_title":"Valutazione di costo-efficacia di ponatinib nella terapia della Leucemia Mieloide Cronica in Italia - HPS","og_url":"https:\/\/hpsitaly.healthcare\/en\/aboutpharmacoeconomics-eng\/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia\/","og_site_name":"HPS","article_published_time":"2015-11-30T17:00:30+00:00","article_modified_time":"2022-04-11T16:27:02+00:00","og_image":[{"width":574,"height":827,"url":"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2015\/11\/VALUTAZIONE-DI-COSTO-EFFICACIA-DI-PONATINIB-NELLA-TERAPIA-DELLA-LEUCEMIA-MIELOIDE-CRONICA-IN-ITALIA.png","type":"image\/png"}],"author":"Eleonora Zaghis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Eleonora Zaghis","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/hpsitaly.healthcare\/en\/aboutpharmacoeconomics-eng\/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia\/","url":"https:\/\/hpsitaly.healthcare\/en\/aboutpharmacoeconomics-eng\/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia\/","name":"Valutazione di costo-efficacia di ponatinib nella terapia della Leucemia Mieloide Cronica in Italia - HPS","isPartOf":{"@id":"https:\/\/hpsitaly.healthcare\/#website"},"primaryImageOfPage":{"@id":"https:\/\/hpsitaly.healthcare\/en\/aboutpharmacoeconomics-eng\/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia\/#primaryimage"},"image":{"@id":"https:\/\/hpsitaly.healthcare\/en\/aboutpharmacoeconomics-eng\/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia\/#primaryimage"},"thumbnailUrl":"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2015\/11\/VALUTAZIONE-DI-COSTO-EFFICACIA-DI-PONATINIB-NELLA-TERAPIA-DELLA-LEUCEMIA-MIELOIDE-CRONICA-IN-ITALIA.png","datePublished":"2015-11-30T17:00:30+00:00","dateModified":"2022-04-11T16:27:02+00:00","author":{"@id":"https:\/\/hpsitaly.healthcare\/#\/schema\/person\/ac9678267e7fdb22ca687b10475393bd"},"breadcrumb":{"@id":"https:\/\/hpsitaly.healthcare\/en\/aboutpharmacoeconomics-eng\/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/hpsitaly.healthcare\/en\/aboutpharmacoeconomics-eng\/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/hpsitaly.healthcare\/en\/aboutpharmacoeconomics-eng\/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia\/#primaryimage","url":"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2015\/11\/VALUTAZIONE-DI-COSTO-EFFICACIA-DI-PONATINIB-NELLA-TERAPIA-DELLA-LEUCEMIA-MIELOIDE-CRONICA-IN-ITALIA.png","contentUrl":"https:\/\/hpsitaly.healthcare\/wp-content\/uploads\/2015\/11\/VALUTAZIONE-DI-COSTO-EFFICACIA-DI-PONATINIB-NELLA-TERAPIA-DELLA-LEUCEMIA-MIELOIDE-CRONICA-IN-ITALIA.png","width":574,"height":827,"caption":"VALUTAZIONE DI COSTO-EFFICACIA DI PONATINIB NELLA TERAPIA DELLA LEUCEMIA MIELOIDE CRONICA IN ITALIA"},{"@type":"BreadcrumbList","@id":"https:\/\/hpsitaly.healthcare\/en\/aboutpharmacoeconomics-eng\/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/hpsitaly.healthcare\/en\/"},{"@type":"ListItem","position":2,"name":"Valutazione di costo-efficacia di ponatinib nella terapia della Leucemia Mieloide Cronica in Italia"}]},{"@type":"WebSite","@id":"https:\/\/hpsitaly.healthcare\/#website","url":"https:\/\/hpsitaly.healthcare\/","name":"HPS","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/hpsitaly.healthcare\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/hpsitaly.healthcare\/#\/schema\/person\/ac9678267e7fdb22ca687b10475393bd","name":"Eleonora Zaghis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/hpsitaly.healthcare\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11db2ac5895a8a4b942ea1e775b297fb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11db2ac5895a8a4b942ea1e775b297fb?s=96&d=mm&r=g","caption":"Eleonora Zaghis"},"url":"https:\/\/hpsitaly.healthcare\/en\/author\/eleonora-zaghis\/"}]}},"_links":{"self":[{"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/posts\/544375","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/users\/64199"}],"replies":[{"embeddable":true,"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/comments?post=544375"}],"version-history":[{"count":4,"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/posts\/544375\/revisions"}],"predecessor-version":[{"id":545943,"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/posts\/544375\/revisions\/545943"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/media\/545229"}],"wp:attachment":[{"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/media?parent=544375"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/categories?post=544375"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hpsitaly.healthcare\/en\/wp-json\/wp\/v2\/tags?post=544375"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}